Risk factors
SELLAS Life Sciences Group (SLS) risk factors
Item 1A of every SELLAS Life Sciences Group, Inc. 10-K on file, and what changed from one year to the next. Readings are automated and can be wrong; check the filing for the exact wording.
- FY2025 10-K risk factors75 risks6 new8 dropped11 reworded
Future Phase 3 trials may face FDA diversity-plan requirements, while enrollment delays could raise costs and extend timelines.
Filed Mar 19, 2026 - FY2024 10-K risk factors77 risks
The company relies heavily on clinical success and financing for its lead drug candidates, GPS and SLS009. Operations depend significantly on third-party manufacturers, license agreements with MSK and GenFleet, and navigating complex regulatory pathways.
Filed Mar 20, 2025